Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 Cell in Refractory Systemic Lupus Erythematosus
NCT06943937Phase 1Terminated
- Sponsor
- China Immunotech
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in systemic lupus erythematosus (SLE), lupus nephritis (LN) and immune thrombocytopenia (ITP), sponsored by China Immunotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Started Apr 2025; status: terminated.
02
Drugs
YTS-109
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06943937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943937.